OneTwenty Opens Closed Beta Applications
OneTwenty opens applications for its Real-Time Longevity closed beta, combining wearable data, smart home biometrics, lab work and clinician-guided programs at a founder rate.
New York, NY
OneTwenty, the company pioneering Real-Time Longevity (RTL), has officially opened applications for its closed beta. Early participants will gain access to a system that integrates wearable data, at-home smart scales and optional blood pressure monitors with on-demand lab work, annual biomarker testing and personalized medical support.
The closed beta invites a select group of participants to help shape the future of personalized, data-driven healthcare. Members receive full access at a founder rate of $499, which includes over $700 worth of lab testing, and early access to the RTL platform that connects biometric tracking with real medical interventions.
Applications are evaluated on each participant’s commitment to improving their health and their engagement with modern wellness tools. Priority goes to people who already use, or plan to use, smart scales, peptides, hormone replacement therapy (HRT or TRT), GLP-1 medications and other longevity interventions.
“When I ran my first hormone panel in 2022, I got a $300 PDF and no real insight. We built OneTwenty to close that gap by connecting how you sleep, train and recover with what’s happening in your blood. This is the foundation of Real-Time Longevity.”
Hayim Pinson, Founder of OneTwenty
What members get
OneTwenty brings together wearable data from Oura, Withings, Apple Health, Fitbit, Dexcom and others with smart scale and blood pressure readings to deliver physician-guided programs across hormone optimization, metabolic weight loss, sleep and recovery. Members gain access to licensed clinicians, prescriptions and targeted therapies, including HRT, TRT, GLP-1 medications and peptide-based interventions, for a complete approach to healthy longevity.
Applications for the closed beta are open now and are reviewed on a rolling basis.


